The endocannabinoid CB 1 receptor has been implicated in the inhibitory control of learning and memory. In the present experiment, we compared the behavioral response of CB 1 receptor knockout mice (CB 1 R À/À ) with animals administered CB 1 receptor antagonist/ inverse agonist SR141716A (rimonabant; 3 mg/kg IP, 30 min pre-trial) in terms of acquisition and retention of a habituation task and changes in cerebral monoamines. The results can be summarized as follows: (i) the acute and chronic invalidation of the CB 1 receptor resulted in an increase of behavioral habituation during the first exposure to an open field, indicative of enhanced acquisition of the task; (ii) CB 1 R À/À mice, but not rimonabant-treated animals, showed enhanced retention of the habituation task when re-tested 48 h and 1 week subsequent to the first exposure to the open field, respectively; (iii) the facilitation of retention of the habituation task in CB 1 R À/À mice was accompanied by a selective and site-specific increase in serotonin activity in hippocampus; and (iv) rimonabant-treated animals displayed 'antidepressant-like' neurochemical alterations of cerebral monoamines, that is, most parameters of monoaminergic activity were increased especially in dorsal striatum and hippocampus. Taken together, the present findings demonstrate that the genetic disruption of the CB 1 receptor gene can cause an improvement of behavioral habituation, which is considered to represent a form of 'non-associative' learning. Furthermore, our data support the assumption of a rimonabant-sensitive cannabinoid receptive site that is different from the 'classical' CB 1 receptor and which, under physiological conditions, might be involved in the inhibitory control of the acquisition but not retention of non-associative learning tasks.
Introduction
The endocannabinoid system is an important neuromodulatory system in the brain. Several neuropsychological functions are under control of the cannabinoid receptor subtype 1 (CB 1 receptor) and of its endogenous lipid ligands anandamide and 2-arachidonoylglycerol, respectively. CB 1 receptors are present at different levels in several brain regions like frontal cortex, dorsal/ventral (nucleus accumbens) striatum, hippocampal formation, septum, and amygdala complex (Fride, 2005; Marsicano & Lutz, 2006 ). At physiological and pathophysiological level, endocannabinoids have been shown to play regulatory roles in several 'integrative' behavioral responses including locomotion, anxiety-and depressive-like states as well as cardiovascular, feeding, and pain control (Pacher, Batkai, & Kunos, 2006) . Of special interest is the potential role of endocannabinoids in 'cognitive' functioning, that is, neural processes related to
